These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 18673245)
21. New avenues to target Wnt/β-catenin signaling. Verkaar F; Zaman GJ Drug Discov Today; 2011 Jan; 16(1-2):35-41. PubMed ID: 21111060 [TBL] [Abstract][Full Text] [Related]
22. Renal carcinogenesis--insights into signaling pathways. Cojocaru E; Lozneanu L; Giuşcă SE; Căruntu ID; Danciu M Rom J Morphol Embryol; 2015; 56(1):15-9. PubMed ID: 25826482 [TBL] [Abstract][Full Text] [Related]
23. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. Pez F; Lopez A; Kim M; Wands JR; Caron de Fromentel C; Merle P J Hepatol; 2013 Nov; 59(5):1107-17. PubMed ID: 23835194 [TBL] [Abstract][Full Text] [Related]
24. Is Wilms tumor a candidate neoplasia for treatment with WNT/β-catenin pathway modulators?--A report from the renal tumors biology-driven drug development workshop. Perotti D; Hohenstein P; Bongarzone I; Maschietto M; Weeks M; Radice P; Pritchard-Jones K Mol Cancer Ther; 2013 Dec; 12(12):2619-27. PubMed ID: 24258344 [TBL] [Abstract][Full Text] [Related]
25. Quantitative proteomics to study a small molecule targeting the loss of von Hippel-Lindau in renal cell carcinomas. Bouhamdani N; Joy A; Barnett D; Cormier K; Léger D; Chute IC; Lamarre S; Ouellette R; Turcotte S Int J Cancer; 2017 Aug; 141(4):778-790. PubMed ID: 28486780 [TBL] [Abstract][Full Text] [Related]
26. Aberrant activation of Wnt/β-catenin signaling pathway contributes to the sequential progression of DMBA-induced HBP carcinomas. Vidya Priyadarsini R; Senthil Murugan R; Nagini S Oral Oncol; 2012 Jan; 48(1):33-9. PubMed ID: 21924667 [TBL] [Abstract][Full Text] [Related]
27. Reduced E-cadherin facilitates renal cell carcinoma progression by WNT/β-catenin signaling activation. Zhang X; Yang M; Shi H; Hu J; Wang Y; Sun Z; Xu S Oncotarget; 2017 Mar; 8(12):19566-19576. PubMed ID: 28223537 [TBL] [Abstract][Full Text] [Related]
28. A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer. Prosperi JR; Goss KH Curr Drug Targets; 2010 Sep; 11(9):1074-88. PubMed ID: 20545611 [TBL] [Abstract][Full Text] [Related]
29. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia. Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510 [TBL] [Abstract][Full Text] [Related]
30. Atypical regulators of Wnt/β-catenin signaling as potential therapeutic targets in Hepatocellular Carcinoma. Chen J; Rajasekaran M; Hui KM Exp Biol Med (Maywood); 2017 Jun; 242(11):1142-1149. PubMed ID: 28429652 [TBL] [Abstract][Full Text] [Related]
32. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836 [TBL] [Abstract][Full Text] [Related]
33. Direct targeting of β-catenin: Inhibition of protein-protein interactions for the inactivation of Wnt signaling. Hahne G; Grossmann TN Bioorg Med Chem; 2013 Jul; 21(14):4020-6. PubMed ID: 23566764 [TBL] [Abstract][Full Text] [Related]
34. The roles of APC and Axin derived from experimental and theoretical analysis of the Wnt pathway. Lee E; Salic A; Krüger R; Heinrich R; Kirschner MW PLoS Biol; 2003 Oct; 1(1):E10. PubMed ID: 14551908 [TBL] [Abstract][Full Text] [Related]
35. Recent Development of Wnt Signaling Pathway Inhibitors for Cancer Therapeutics. Harb J; Lin PJ; Hao J Curr Oncol Rep; 2019 Feb; 21(2):12. PubMed ID: 30715618 [TBL] [Abstract][Full Text] [Related]
36. Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells. Sutphin PD; Chan DA; Li JM; Turcotte S; Krieg AJ; Giaccia AJ Cancer Res; 2007 Jun; 67(12):5896-905. PubMed ID: 17575159 [TBL] [Abstract][Full Text] [Related]
37. The Wnt/beta-catenin signaling pathway as a target in drug discovery. Takahashi-Yanaga F; Sasaguri T J Pharmacol Sci; 2007 Aug; 104(4):293-302. PubMed ID: 17721040 [TBL] [Abstract][Full Text] [Related]
38. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Fodde R; Brabletz T Curr Opin Cell Biol; 2007 Apr; 19(2):150-8. PubMed ID: 17306971 [TBL] [Abstract][Full Text] [Related]
39. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas. Roskoski R Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784 [TBL] [Abstract][Full Text] [Related]
40. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance. Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]